Telesis Bio (TBIO) announced a new license agreement with Regeneron Pharmaceuticals (REGN) to deploy Telesis Bio’s Gibson SOLA platform at its R&D core facilities. The company stated this will help Regeneron adopt automated, high-throughput, on-demand gene synthesis in their own labs, aiming to accelerate biologics discovery timelines from weeks to hours. The Gibson SOLA platform is designed to enable fully-enzymatic, overnight, on-site synthesis of high-fidelity DNA and mRNA.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.